Telix Presentation at the European Multidisciplinary Congress on Urological Cancers
Telix recently presented at the 12th European Multidisciplinary Congress on Urological Cancers entitled: “New Perspectives in Prostate and Kidney Cancer”.
Telix Receives €545,000 Belgian Research Grant for Prostate Cancer Imaging Agent in Europe
Advanced Nuclear Medicine Ingredients S.A. (ANMI) announces a €545,000 payment from the Walloon regional government in Belgium.
Telix presentations at European Association of Nuclear Medicine 2020 Satellite Symposium
Telix sponsored a session at the recent EANM20 Satellite Symposium, entitled “Next Generation Imaging with PSMA-PET & More”. For those unable to attend, we are pleased to provide recordings of live presentations held on 29th October 2020.
Investor Briefing: Telix Pharmaceuticals Limited and China Grand Pharma Partnership
Telix Pharmaceuticals Provides Investor Briefing: Our Asian Future
Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market
Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market.
Activity Report and Sales Note to Accompany Appendix 4C
Telix Pharmaceuticals provides its Activity Report and Appendix 4C for the quarter ending 30th September 2020, and Q3 2020 sales update for its prostate cancer imaging product.
Telix Japan to Present at Japanese Society of Nuclear Medicine Annual Scientific Meeting
Telix Japan is pleased to announce it will be presenting at the Annual Scientific Meeting of the Japanese Society of Nuclear Medicine (JSNM-JSNMT2020) to be held 12-14th November 2020 at Kobe International Conference Center.
Telix Completes Licence Agreement with German Cancer Research Center (DKFZ) for Image-Guided Prostate Surgery
Telix has secured an exclusive Intellectual Property licence agreement with the German Cancer Research Center (DKFZ) for a novel imaging technology in the field of image-guided surgery for prostate cancer.
Completion of Phase I Enrolment of Japanese Renal Cancer Study
Telix Pharmaceuticals Japan K.K. is pleased to announce the completion of Phase I enrolment of the Company’s Phase I/II ZIRDAC-JP study of Telix’s renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab) in Japan.
First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product in Turkey
Telix and Eczacıbaşı-Monrol Nuclear Products Co. are pleased to announce that the first patients have been dosed in Telix’s Phase III ZIRCON clinical trial